---
title: "Simcere’s Sanbexin Sublingual Tablets Added to China’s 2026 Reimbursement List"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305584992.md"
description: "Simcere Pharmaceutical Group announced that its Sanbexin sublingual tablets have been added to China’s 2026 national reimbursement drug list, effective January 1, 2027. The company also noted that the Sanbexin injection completed its third renewal. Simcere is an R&D-driven pharmaceutical firm specializing in neuroscience and oncology therapies."
datetime: "2026-11-15T23:13:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305584992.md)
  - [en](https://longbridge.com/en/news/305584992.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305584992.md)
generator: "portal-rs"
---

# Simcere’s Sanbexin Sublingual Tablets Added to China’s 2026 Reimbursement List

Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.

Simcere Pharmaceutical Group is an innovation- and R&D-driven pharmaceutical company focused on neuroscience, anti-oncology, autoimmune and anti-infection therapies. On November 14, 2026, its Sanbexin sublingual tablets were included in China’s 2026 national reimbursement drug list, effective January 1, 2027, while Sanbexin injection completed its third renewal.

Sanbexin combines edaravone and dexborneol and can be used sequentially with the injection for treatment in hospital and after discharge. The tablets were approved in China in December 2024 and received U.S. FDA Breakthrough Therapy designation in August 2024.

### Related Stocks

- [02096.HK](https://longbridge.com/en/quote/02096.HK.md)

## Related News & Research

- [Simcere Receives China Clinical Trial Approval for SIM0725](https://longbridge.com/en/news/305008431.md)
- [Simcere Pharmaceutical Files Next-Day Return to HKEX Disclosing Share Buyback for Cancellation](https://longbridge.com/en/news/305154933.md)
- [Simcere Wins German Approval for Phase 1 Trial of SIM0709](https://longbridge.com/en/news/304825298.md)
- [China Accepts Simcere’s Zemprocitinib Application for Rheumatoid Arthritis Review](https://longbridge.com/en/news/304574909.md)
- [Hansoh Adds Three Innovative-Medicine Indications to 2026 NRDL](https://longbridge.com/en/news/305581132.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**